{"transactions":[{"id":710681,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2026-07-13T20:10:17.000Z","date":"2026-07-10","kind":"sale","planned":true,"acquired":false,"shares":68289,"price":20.02,"value":1367145.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2774893,"source":{"system":"sec-edgar","filing":"0001213900-26-077564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390026077564/ownership.xml","form_type":"4"}},{"id":710680,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2026-07-13T20:10:17.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":33936,"price":20.01,"value":679059.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2843182,"source":{"system":"sec-edgar","filing":"0001213900-26-077564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390026077564/ownership.xml","form_type":"4"}},{"id":718477,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2026-07-02T20:10:21.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":47775,"price":20.03,"value":956933.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2877118,"source":{"system":"sec-edgar","filing":"0001213900-26-074964","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390026074964/ownership.xml","form_type":"4"}},{"id":808915,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2026-04-14T21:55:59.000Z","date":"2026-04-13","kind":"sale","planned":false,"acquired":false,"shares":51873,"price":18.23,"value":945644.79,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended."}],"balance_after":2924893,"source":{"system":"sec-edgar","filing":"0001213900-26-043647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390026043647/ownership.xml","form_type":"4"}},{"id":808914,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2026-04-14T21:55:59.000Z","date":"2026-04-10","kind":"sale","planned":false,"acquired":false,"shares":98127,"price":18.41,"value":1806518.07,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $19.55. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended."}],"balance_after":2976766,"source":{"system":"sec-edgar","filing":"0001213900-26-043647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390026043647/ownership.xml","form_type":"4"}},{"id":942345,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:01:04.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":520342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":520342,"derivative":{"exercise_price":11.29,"expiration_date":"2036-01-07","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":520342},"source":{"system":"sec-edgar","filing":"0001213900-26-002906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390026002906/ownership.xml","form_type":"4"}},{"id":961155,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common shares, par value CHF 0.10 per share, of MoonLake AG","published_at":"2025-12-22T21:01:24.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":false,"shares":5836,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"10,000 of the common shares of MoonLake AG held by the holder (the \"second leaver shares\") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the \"second vesting period\"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest."},{"field":"security","element":"securityTitle","label":"F4","text":"(continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 19, 2025, the Reporting Person exchanged 5,836 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 196,316 Class A ordinary shares of the Issuer. In connection with the exchange, 196,316 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":196316},"source":{"system":"sec-edgar","filing":"0001213900-25-124510","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390025124510/ownership.xml","form_type":"4"}},{"id":961154,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class C ordinary shares, par value $0.0001 per share","published_at":"2025-12-22T21:01:24.000Z","date":"2025-12-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":196316,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"security","element":"securityTitle","label":"F3","text":"10,000 of the common shares of MoonLake AG held by the holder (the \"second leaver shares\") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the \"second vesting period\"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest."},{"field":"security","element":"securityTitle","label":"F4","text":"(continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 19, 2025, the Reporting Person exchanged 5,836 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 196,316 Class A ordinary shares of the Issuer. In connection with the exchange, 196,316 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-25-124510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390025124510/ownership.xml","form_type":"4"}},{"id":961153,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2025-12-22T21:01:24.000Z","date":"2025-12-19","kind":"exercise","planned":false,"acquired":true,"shares":196316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 19, 2025, the Reporting Person exchanged 5,836 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 196,316 Class A ordinary shares of the Issuer. In connection with the exchange, 196,316 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":3074893,"source":{"system":"sec-edgar","filing":"0001213900-25-124510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390025124510/ownership.xml","form_type":"4"}},{"id":974679,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2025-12-10T21:29:45.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":70000,"price":14.49,"value":1014300.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales."}],"balance_after":2878577,"source":{"system":"sec-edgar","filing":"0001213900-25-120106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390025120106/ownership.xml","form_type":"4"}},{"id":974678,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2025-12-10T21:29:45.000Z","date":"2025-12-08","kind":"sale","planned":false,"acquired":false,"shares":130000,"price":15.08,"value":1960400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.045789 to $15.098641. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales."}],"balance_after":2948577,"source":{"system":"sec-edgar","filing":"0001213900-25-120106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390025120106/ownership.xml","form_type":"4"}},{"id":1236231,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2025-03-04T02:08:08.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":95763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of restricted stock that vest in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":3078577,"source":{"system":"sec-edgar","filing":"0001213900-25-019674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390025019674/ownership.xml","form_type":"4"}},{"id":1610332,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2024-03-01T00:56:32.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":4740,"price":55.89,"value":264918.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.50 to $57.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2982814,"source":{"system":"sec-edgar","filing":"0001213900-24-018675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390024018675/ownership.xml","form_type":"4"}},{"id":1610331,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2024-03-01T00:56:32.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":56065,"price":55,"value":3083575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023."}],"balance_after":2987554,"source":{"system":"sec-edgar","filing":"0001213900-24-018675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390024018675/ownership.xml","form_type":"4"}},{"id":1610330,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2024-03-01T00:56:32.000Z","date":"2024-02-27","kind":"sale","planned":true,"acquired":false,"shares":62810,"price":55,"value":3454550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023."}],"balance_after":3043619,"source":{"system":"sec-edgar","filing":"0001213900-24-018675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390024018675/ownership.xml","form_type":"4"}},{"id":1622895,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2024-02-23T21:48:13.000Z","date":"2024-02-21","kind":"sale","planned":true,"acquired":false,"shares":1125,"price":55.27,"value":62178.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.025 to $55.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":3106429,"source":{"system":"sec-edgar","filing":"0001213900-24-016544","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390024016544/ownership.xml","form_type":"4"}},{"id":1634305,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2024-02-20T23:36:56.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":57.44,"value":1148800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.115 to $59.21. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":3107554,"source":{"system":"sec-edgar","filing":"0001213900-24-015446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390024015446/ownership.xml","form_type":"4"}},{"id":1634304,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2024-02-20T23:36:56.000Z","date":"2024-02-16","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":60.15,"value":1203000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.335 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":3127554,"source":{"system":"sec-edgar","filing":"0001213900-24-015446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390024015446/ownership.xml","form_type":"4"}},{"id":1634303,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2024-02-20T23:36:56.000Z","date":"2024-02-15","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":60.18,"value":1203600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 17, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.185 to $63.95. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"Commission\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":3147554,"source":{"system":"sec-edgar","filing":"0001213900-24-015446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000121390024015446/ownership.xml","form_type":"4"}},{"id":1768030,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common shares, par value CHF 0.10 per share, of MoonLake AG","published_at":"2023-10-03T23:28:44.000Z","date":"2023-10-01","kind":"exercise","planned":false,"acquired":false,"shares":4164,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"10,000 of the common shares of MoonLake AG held by the holder (the \"second leaver shares\") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the \"second vesting period\"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a \"Change of Control\"), the unvested second leaver shares will fully vest."},{"field":"security","element":"securityTitle","label":"F4","text":"(continued from footnote 4) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":5836,"derivative":{"underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":140071},"source":{"system":"sec-edgar","filing":"0001013762-23-001297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000101376223001297/ownership.xml","form_type":"4"}},{"id":1768029,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common shares, par value CHF 0.10 per share, of MoonLake AG","published_at":"2023-10-03T23:28:44.000Z","date":"2023-10-01","kind":"exercise","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":3027483},"source":{"system":"sec-edgar","filing":"0001013762-23-001297","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000101376223001297/ownership.xml","form_type":"4"}},{"id":1768028,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class C ordinary shares, par value $0.0001 per share","published_at":"2023-10-03T23:28:44.000Z","date":"2023-10-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":140071,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"security","element":"securityTitle","label":"F3","text":"10,000 of the common shares of MoonLake AG held by the holder (the \"second leaver shares\") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the \"second vesting period\"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a \"Change of Control\"), the unvested second leaver shares will fully vest."},{"field":"security","element":"securityTitle","label":"F4","text":"(continued from footnote 4) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":217374,"source":{"system":"sec-edgar","filing":"0001013762-23-001297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000101376223001297/ownership.xml","form_type":"4"}},{"id":1768027,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2023-10-03T23:28:44.000Z","date":"2023-10-01","kind":"exercise","planned":false,"acquired":true,"shares":140071,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":3167554,"source":{"system":"sec-edgar","filing":"0001013762-23-001297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000101376223001297/ownership.xml","form_type":"4"}},{"id":1768026,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class C ordinary shares, par value $0.0001 per share","published_at":"2023-10-03T23:28:44.000Z","date":"2023-10-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3027483,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001013762-23-001297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000101376223001297/ownership.xml","form_type":"4"}},{"id":1768025,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":30837,"kind":"person","name":"Santos da Silva Jorge","position":1,"cik":"0001920509","reported_name":"Santos da Silva Jorge","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A ordinary shares, par value $0.0001 per share","published_at":"2023-10-03T23:28:44.000Z","date":"2023-10-01","kind":"exercise","planned":false,"acquired":true,"shares":3027483,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG (\"MoonLake AG\") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled."}],"balance_after":3027483,"source":{"system":"sec-edgar","filing":"0001013762-23-001297","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920509/000101376223001297/ownership.xml","form_type":"4"}}]}